Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced), Stage IIC Melanoma (Locally Advanced), Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma (Limited, Resectable)
Conditions
Keywords
Melanoma, B-RAF, biomarkers, targeted therapy, resistance
Brief summary
This phase II trial studies how well giving dabrafenib alone and in combination with trametinib before surgery works in treating patients with advanced melanoma that can be removed by surgery. Studying samples of tumor tissue in the laboratory from patients receiving dabrafenib and trametinib may help doctors learn more about the effects of these drugs on cells and help identify biomarkers that determine which patients will respond to these drugs best.
Detailed description
PRIMARY OBJECTIVES: I. To identify markers of intrinsic resistance to v-Raf murine sarcoma viral oncogene homolog B1 (B-RAF) targeted therapy in B-RAF mutation-positive melanoma. SECONDARY OBJECTIVES: I. To determine if intrinsic resistance can be reversed by mitogen activated protein kinase (MEK) targeted therapy and to identify biomarkers that correlate with this response. II. To evaluate the feasibility of pre-surgical targeted therapy and serial tumor biopsies in patients with advanced, operable melanoma to determine if this model can be used to evaluate novel combinations of molecular targeted therapy in the future. TERTIARY OBJECTIVES: I. To determine if pre-surgical B-RAF and MEK targeted therapy is active and well tolerated in patients with advanced, operable melanoma. These findings may be used to support clinical trials in un-resectable, B-RAF mutation-positive melanoma. OUTLINE: Patients receive dabrafenib orally (PO) twice daily (BID) on days 1-28 adding trametinib on days 15-28 followed by surgery on days 28-30. Treatment continues until the day prior to surgery in the absence of unacceptable toxicity. After completion of study treatment, patients are followed up for 3 months.
Interventions
DRUGdabrafenib
150 mg given PO
DRUGtrametinib
2 mg given PO
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
National Comprehensive Cancer Network
Vanderbilt-Ingram Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Signed written informed consent * Patients with locally-or regionally advanced melanoma being considered for resection of the lesion(s) for local-regional control and potential cure * Patients with limited, resectable metastatic disease (three or fewer lesions) are eligible if surgical resection is considered to be the best therapeutic option * Patients with AJCC clinical stage IIb-IV disease at initial diagnosis, or patients with melanoma of any stage with advanced local or regional recurrence, with or without limited resectable metastatic disease, would be eligible * B-RAF V-600 mutation positive by snapshot molecular analysis * Individuals with B-RAF V-600 mutations other than V600E are eligible * Measurable disease, i.e. presenting with at least one measurable lesion per Response Evaluation Criteria in Solid tumors (RECIST) 1.1 * All prior treatment related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) (Version 4.0) =\< Grade 1 at the time of enrollment * Adequate baseline organ function defined by the criteria below: * Absolute Neutrophil Count (ANC) \>= 1.5 X 10\^9/L * Platelet Count \>= 60 X 10\^9/L * Hemoglobin \>= 9 g/dl * Creatinine =\< 2 mg/dl * Aspartate aminotransferase (AST) =\< 100 U/L * Alanine aminotransferase (ALT) =\< 100 U/L * Alkaline Phosphatase =\< 380 U/L * Total Bilirubin =\< 2.0 mg/dl * Women of childbearing potential must have a negative serum pregnancy test within 14 days of first dose of study treatment and agree to use effective contraception during the study and for 7 days following the last dose of study treatment * Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from 1 day prior to administration of the first dose of study treatment until 7 days after the last dose of study treatment
Exclusion criteria
* ECOG Performance Status \> 2 * Lactating female * Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures * Any serious medical condition that would render the patient unable to undergo surgical resection or would limit life expectancy to less than 1 year * Any prohibited medication * Administration of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment * A known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK-2118436 (dabrafenib) or GSK-1120212 (trametinib) or excipient that contraindicates their participation * Patients with a history of severe cardiovascular disease as defined: * Symptomatic or uncontrolled cardiac arrhythmias * Treatment refractory hypertension, defined as a systolic blood pressure \> 160mm Hg and/or diastolic \> 100 mmHg which cannot be controlled by antihypertensive therapy. * Current ≥ NYHA Class II congestive heart failure * History of myocardial infarction or unstable angina within 6 months prior to study entry. * History of stroke or TIA within 6 months prior to study entry * QTc ≥ 480 msec * Cardiac valvular disease ≥ grade 2. * Patients with a history of interstitial lung disease or interstitial pneumonitis * A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection. * History of another active malignancy within the past 5 years, or any malignancy with a confirmed activating RAS mutation. Please note that prospective RAS mutation testing is not required, however, if results of previous RAS testing are known, they must be used in assessing eligibility. Subjects with a history of completely resected non-melanoma skin cancer are eligible. * A history or current evidence/risk of retinal vein occlusion (RVO) or CSR including: * a. Presence of predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or a history of hyperviscosity or hypercoagulability syndromes); or * b. Visible retinal pathology as assessed by ophthalmic examination that is considered a risk factor for RVO or CSR such as: * i. Evidence of new optic disc cupping; * ii. Evidence of new visual field defects on automated perimetry; * iii. Intraocular pressure \>21 mmHg as measured by tonography.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Tumor Response Rate (Response is Based on Greater Than 30% Reduction From Baseline in Tumor Volume by RECIST Criteria) at Day 14. | day 14 | Tumor response is defined as greater than 30% reduction from baseline in tumor volume by RECIST criteria. To determine whether a patient is responded at day 14, the patient must have the tumor volume evaluated at both baseline and day 14. The tumor response rate is calculated as the proportion of patients responded among all evaluated patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Tumor Volume Reduction in Participants With Intrinsic Resistance to B-RAF Targeted Therapy From Day 14 to Day 28. | Day 14 and day 28 | Tumor volume reduction is calculated as the tumor volume change relative to the baseline measurement (percent). Change in tumor volume reduction from day 14 to day 28 is calculated as the difference of tumor volume reduction at day 28 and day 14. The median and Inter-Quartile Range are reported. |
| Number of Patients With Worst Grade Toxicities by Grade According to National Cancer Institute (NCI) CTCAE Version 4.0 | Up to 3 months | The intensity of the adverse event will be graded according to Version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events (June 14, 2010): Grade 1 - Mild Grade 2 - Moderate Grade 3 - Severe or medically significant Grade 4 - Life-threatening Grade 5 - Death related to adverse event |
| Investigational Agent Taken | Up to 3 months | Median number of pills taken |
| Percent of Patients Completing Second and Third (Surgical) Biopsies | Up to 3 months | Biopsies will be assessed whether or not tissue is acquired at specified time points. Tissue is obtained through core, punch, incisional or excisional biopsy or surgical resection, based upon the clinical situation. Standard operating procedures for biopsies, sample preparation and analysis have been defined. |
| Percentage of Biopsies With Adequate Tissue for Biomarker Analysis | Up to 3 months | Measured by the percent of tumor necrosis on hematoxylin and eosin stains; RNA gel electrophoresis, percent of adequate tissue for immunohistochemical stains in tissue microarray and cyTOF analysis. |
Countries
United States
Participant flow
Recruitment details
This study opened to accrual at Vanderbilt-Ingram Cancer Center (VICC) in January 2013 and ran through March 2015 when it closed prematurely due to PI's departure.
Pre-assignment details
Thirteen patients participated in this study, all completed the study as defined by protocol.
Participants by arm
| Arm | Count |
|---|---|
| Basic Science (Dabrafenib, Trametinib) Patients receive dabrafenib PO BID on days 1-28 adding trametinib on days 15-28 followed by surgery on days 28-30. Treatment continues in the absence of unacceptable toxicity.
dabrafenib: 150 mg given PO
trametinib: 2 mg given PO
laboratory biomarker analysis: Correlative studies | 13 |
| Total | 13 |
Baseline characteristics
| Characteristic | Basic Science (Dabrafenib, Trametinib) |
|---|---|
| Age, Customized 20-29 | 1 Participants |
| Age, Customized 30-39 | 2 Participants |
| Age, Customized 40-49 | 2 Participants |
| Age, Customized 50-59 | 3 Participants |
| Age, Customized 60-69 | 3 Participants |
| Age, Customized 70-79 | 2 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 13 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 13 Participants |
| Region of Enrollment United States | 13 Participants |
| Sex: Female, Male Female | 7 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 13 / 13 |
| serious Total, serious adverse events | 1 / 13 |
Outcome results
Primary
Clinical Tumor Response Rate (Response is Based on Greater Than 30% Reduction From Baseline in Tumor Volume by RECIST Criteria) at Day 14.
Tumor response is defined as greater than 30% reduction from baseline in tumor volume by RECIST criteria. To determine whether a patient is responded at day 14, the patient must have the tumor volume evaluated at both baseline and day 14. The tumor response rate is calculated as the proportion of patients responded among all evaluated patients.
Time frame: day 14
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dabrafenib and Trametinib | Clinical Tumor Response Rate (Response is Based on Greater Than 30% Reduction From Baseline in Tumor Volume by RECIST Criteria) at Day 14. | 0.833 proportion of responders |
Secondary
Change in Tumor Volume Reduction in Participants With Intrinsic Resistance to B-RAF Targeted Therapy From Day 14 to Day 28.
Tumor volume reduction is calculated as the tumor volume change relative to the baseline measurement (percent). Change in tumor volume reduction from day 14 to day 28 is calculated as the difference of tumor volume reduction at day 28 and day 14. The median and Inter-Quartile Range are reported.
Time frame: Day 14 and day 28
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dabrafenib and Trametinib | Change in Tumor Volume Reduction in Participants With Intrinsic Resistance to B-RAF Targeted Therapy From Day 14 to Day 28. | 18.0 percentage of reduction |
Secondary
Investigational Agent Taken
Median number of pills taken
Time frame: Up to 3 months
| Arm | Measure | Group | Value (MEDIAN) | Dispersion |
|---|---|---|---|---|
| Dabrafenib and Trametinib | Investigational Agent Taken | Median number of GSK1120212 taken | 13 Number of pills taken | Standard Deviation 1.9 |
| Dabrafenib and Trametinib | Investigational Agent Taken | Median number of GSK2118436 taken | 54 Number of pills taken | Standard Deviation 6.34 |
Secondary
Number of Patients With Worst Grade Toxicities by Grade According to National Cancer Institute (NCI) CTCAE Version 4.0
The intensity of the adverse event will be graded according to Version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events (June 14, 2010): Grade 1 - Mild Grade 2 - Moderate Grade 3 - Severe or medically significant Grade 4 - Life-threatening Grade 5 - Death related to adverse event
Time frame: Up to 3 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dabrafenib and Trametinib | Number of Patients With Worst Grade Toxicities by Grade According to National Cancer Institute (NCI) CTCAE Version 4.0 | Number of patients with worst-grade toxicity 1 | 1 participants |
| Dabrafenib and Trametinib | Number of Patients With Worst Grade Toxicities by Grade According to National Cancer Institute (NCI) CTCAE Version 4.0 | Number of patients with worst-grade toxicity 2 | 6 participants |
| Dabrafenib and Trametinib | Number of Patients With Worst Grade Toxicities by Grade According to National Cancer Institute (NCI) CTCAE Version 4.0 | Number of patients with worst-grade toxicity 3 | 6 participants |
| Dabrafenib and Trametinib | Number of Patients With Worst Grade Toxicities by Grade According to National Cancer Institute (NCI) CTCAE Version 4.0 | Number of patients with worst-grade toxicity 4 | 0 participants |
| Dabrafenib and Trametinib | Number of Patients With Worst Grade Toxicities by Grade According to National Cancer Institute (NCI) CTCAE Version 4.0 | Number of patients with worst-grade toxicity 5 | 0 participants |
Secondary
Percentage of Biopsies With Adequate Tissue for Biomarker Analysis
Measured by the percent of tumor necrosis on hematoxylin and eosin stains; RNA gel electrophoresis, percent of adequate tissue for immunohistochemical stains in tissue microarray and cyTOF analysis.
Time frame: Up to 3 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dabrafenib and Trametinib | Percentage of Biopsies With Adequate Tissue for Biomarker Analysis | 92 percentage of biopsies w/adequate tissue |
Secondary
Percent of Patients Completing Second and Third (Surgical) Biopsies
Biopsies will be assessed whether or not tissue is acquired at specified time points. Tissue is obtained through core, punch, incisional or excisional biopsy or surgical resection, based upon the clinical situation. Standard operating procedures for biopsies, sample preparation and analysis have been defined.
Time frame: Up to 3 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dabrafenib and Trametinib | Percent of Patients Completing Second and Third (Surgical) Biopsies | 92 percentage of participants |